Publication
PlasmaCap EBA: An innovative method of isolating plasma proteins from human plasma (online link)
Publication
Publication
22nd Oct 2021 – Las Vegas, NV (October 22nd, 2021) – Evolve presented updated results on behalf of Dr Richard Wasserman from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”
Publication
16 Apr, 2021 – Virtual Meeting (April 16, 2021) – Dr Richard Wasserman presented results from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”. Abstracts available here
Publication
25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”. Abstracts available here.
Publication
24 Feb, 2019 – San Francisco, CA (February 24, 2019) – Dr Richard Wasserman presented “Interim Safety Data in a Prospective, Open-Label, Multi-Center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of PlasmaCap IG in Patients with Primary Immunodeficiency Diseases (PIDDs)”. Abstract published in Journal of Allergy Clinical Immunology (JACI).
Publication
19 Oct, 2018 – Dallas, TX (October 19, 2018) – Evolve presented “A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCapTM IG (Immunoglobulin) in adults and children with primary immunodeficiency” and “PlasmaCap EBA™, an innovative method of isolating plasma proteins from human plasma”. Abstracts available here.